Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Sagimet Biosciences Inc.
organization2 mentionslast seen Oct 1, 2026
Clinical-stage biopharmaceutical company developing novel FASN inhibitors for metabolic and fibrotic pathways.
Relationships 8
- Sagimet Biosciences Inc.employsDavid Happel99% confidence2 sources
- Sagimet Biosciences Inc.developsTVB-356799% confidence2 sources
- Sagimet Biosciences Inc.developsdenifanstat99% confidence2 sources
- Sagimet Biosciences Inc.employsAndreas Grauer98% confidence1 source
- Sagimet Biosciences Inc.funded bySeries A Common Stock offering94% confidence1 source
- Sagimet Biosciences Inc.partners withTAPI88% confidence1 source
- Sagimet Biosciences Inc.developsfatty acid synthase inhibitor85% confidence1 source
- Sagimet Biosciences Inc.invests inAscletis BioScience Co. Ltd.70% confidence1 source
Relationship
Sagimet Biosciences Inc.employsDavid Happel
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGARSep 30, 2026Sagimet Biosciences Inc. 8-K: Item 1.01: Entry into a Material Definitive Agreement; Item 9.01: Financial Statements and Exhibits
David Happel Chief Executive Officer
- filingSEC EDGARSep 30, 2026Sagimet Biosciences Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
David Happel Chief Executive Officer